Genetically Modified Macrophages: A Treatment for Multiple Lung Diseases?

CAR T Cell Therapy: Magic Bullet or Well-aimed Shot in the Dark?

The renal artery: A one-way street to fixing the kidney?

Developing a resource to support Research Ethics Committees reviewing gene therapy trials

Gene and cell therapies have come a long way, but what is happening next according to stakeholders?

Cancer Viro-Immunotherapy: Repurposing the Past to Shape the Future

Commercialising Academic Research: Risk and Opportunity

Making gene and cell therapy possible: Viruses

Researcher in the Spotlight: Alexandros Angelopoulos, Northumbria University

Down but not out: how adenoviral vaccines may still save the day.

An update on gene therapy for Spinal muscular atrophy

First in man in vivo delivery of CRISPR-Cas9 targeting Transthyretin Amyloidosis

Vaccines for COVID-19

A Commentary on Vaccine-Induced Immune Thrombotic Thrombocytopenia

See you LATER to pain

Addressing the challenge of informing the wider population on advances in gene and cell therapy

Precision genome editing for mitochondrial DNA – Mission accomplished?

Switching Up T Cell Therapies

Could It Be A One-Stop Solution For The Most Common Cause Of Irreversible Blindness?

The Churchillian dilemma of Gene Editing

Rebuilding the brain with stem cells: is it a no-brainer?

Skin; Lets Break It Down

CRISPR-engineered T cells in patients with refractory cancer

Precision correction of pathogenic mutations using prime editing technology

Programmed to kill: Synthetic virology to attack cancer

Gene-loaded sutures to promote tendon healing

3D Printing of Personalized Cardiac Patches and Hearts

Retirement of Prof George Dickson, a founder of British Society for Gene and Cell Therapy

The origin of your noggin

Human Germline Editing – What’s the big deal?

One image at a time: using cryoEM to unpick how viruses infect cells

A final chance to breathe: Could gene therapy cure cystic fibrosis lung disease?

Cracking the enthesis code

Overcoming the disconnection

Putting the dopamine back in Parkinson’s

Rare is not so rare

It’s an ECR life?